Approved for use through 10/31/2007. OMB 0851-0031 redemark Office; U.S. DEPARTMENT OF COMMERCE

	Under the Paperwork Reduction Act of 1995, no persons are required to	respond to a collection of informa	tion unless it contains a valid OMB control number.	
	Substitute for form 1448/PTO	Complete if Known		
	•	Application Number	10/551,869	
	INFORMATION DISCLOSURE	Filing Date	October 31, 2006	
		First Named Inventor	Ask Püschl	
	STATEMENT BY APPLICANT	Art Unit .	1625	
	(Use as many sheets as necessary)	Examiner Name	Taofiq A. Solola	
S	heet 1 of 1	Attorney Docket Number	433-US-PCT	

# T =				DOCUMENTS	<u> </u>
Examiner C Initiats* . N	ite D.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Retevant Figures Appear
	→.	Number-Kind Code			- rigules Appeal
<u>:: .</u>		US CONTRACTOR			Å.
		US-1 - 1 7	A STATE OF THE STA		₩ 18. 
	T	US-	1		
	T	US-			
	T	US-			
	1	US-			
	1	US-		<del></del>	
	1	US-		<del></del>	
	1	US-			<u>-                                      </u>
<u>:</u>	- 1	US-			a
1.4°		US.			
·	- 1	US-			
	1	US-			\$1.1, <sup>2</sup>
	1	US-			
8.	1	US-			10 to
	1	us-	1		
10 m	一	US-			
- 7.		us-			
1 2	1.0	US-	P. C.		

Cite No.		Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages
	Country Code <sup>a</sup> Number * Kind Code <sup>a</sup> (d known)			Or Relevant Figures Appear
Α		10-14-2004	H. Lundbeck A/S	i i
. <b>B</b>	WO 2004/087156 A1	10-14-2004	H. Lundbeck A/S	
	No.¹	Country Code* Number*** Tignis Code* (st known)  A WO 2004/087155 A1  B WO 2004/087156 A1	Cite No. 1  Course Patient Document Publication Date MM-DD-YYYY  A WO 2004/087155 A1 10-14-2004  B WO 2004/087156 A1 10-14-2004	No. 1 Country Code® Number 1 Toric Code® (of known)  A WO 2004/087155 A1 10-14-2004 H. Lundbeck A/S  B WO 2004/087156 A1 10-14-2004 H. Lundbeck A/S

Examiner Signature	T.A.	Solola	Date Considered	1-25-08

"EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. "Applicant's unique citation designation number (optional)." See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspig.gov.or.MPEP">www.uspig.gov.or.MPEP</a> 901.04. "Enter Office that issued the document, by the two-letter code (MIPO Standard ST.3). "For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. "Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. "Applicant is to place a check mark here if English language Translation is attached."

Transistion is artisched.
This collection of Information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing; and submitting the completed application form to the USPTO. Time will very depending upon the individual case. Any comments on the amount of time you require to complete this form end/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-788-9199) and select option 2.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

\_\_\_\_

Substitute for form 1449/PTO

Sheet 1

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known				
Application Number	10/551,869			
Filing Date	October 31, 2006			
First Named Inventor	Ask Püschl			
Art Unit	1625			
Examiner Name	Not Yet Assigned			
Attorney Docket Number	133 HS DOT			

	**********			DOCUMENTS	······································
Examiner Initials*	No.	Document Number  Number-Kind Code <sup>2 (Finance)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
40	A	<sup>US-</sup> 4,066,654	01-03-1978	Adelstein, G.W., et al.	
	8	<sup>US-</sup> 4,198,419	04-15-1980	Ong, H.H. and Profitt, J.A.	
	С	US-6,677,378 B2	01-13-2004	Howard, H.R., Jr., et al.	
	D	<sup>US-</sup> 7,138,407 B2.	11-21-2006	Ruhland, T., et al.	
	E	<sup>US-</sup> 7,144,884 B2	12-05-2006	Ruhland, T., et al.	
$\mathbb{V}$	F	US- 7,148,238 B2	12-12-2006	Ruhland, T., et al.	
		US-			
••••••		US-			
*****************	1	US-			
	1	US-	*******************************	***************************************	
		US-			
		US-			

*************	***********		PATENT DOCU	IMENTS		*******
Examiner Initiats*	Cite No.		Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> if known	MM-DD-YYYY	7,7,7,000	Or Relevant Figures Appear	で
10	G	WO 99/17777 A1	04-15-1999	Merck & Co., Inc.		
	н	WO 00/50380 A1	08-31-2000	Pfizer Products Inc.		
		WO 04/85385 A2	10-07-2004	Schering Corporation		
\	J	WO 05/00309 A2	01-06-2005	Ionix Pharmaceuticals Limited		
-						

		**********	*************			
Examiner			011	Date		
Mark and an		711	5 - 1 1	; Date	- 1	1 2
Signature		//\.^	101516	1 Consid	aran'	$I - \nu S - D V$
	: /			1 00.1000	0160 {	1-10
		XX		2		, ,

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.cov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to tile (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	Substitute for form 1449/PTO			Complete if Known		
				Application Number	10/551,869	
			SCLOSURE	Filing Date	October 31, 2006	
STA	ATEMENT E	BY A	PPLICANT	First Named Inventor	Ask Püschl	
	(Use as many sho	oots as i	necessary)	Art Unit	1625	
				Examiner Name	Not Yet Assigned	
Sheet	2	of	3	Attorney Docket Number	433-US-PCT	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
40	K	Buckle, D.R. and Rockell, C.J.M., "A Versatile Two-Stage Synthesis of 2-Substituted Benzo [b]furans from (2-Methoxyphenyl)ethynes". J. Chem. Soc. Perkin Trans. I, 1985: 2443-2446.	
	.L	Clayden, J., "Regioselective Synthesis of Organolithiums by X-Li Exchange." In Organolithiums: Selectivity for Synthesis. Tetrahedron Organic Chemistry Series. 2002, New York, Pergamon. 23: 111-147.	
	М	Dabrowski, M., et al. "Halogen-lithium exchange between substituted dihalobenzenes and butyllithium: application to the regioselective synthesis of functionalized bromobenzaldehydes." Tetrahedron. 2005. 61:6590-6595.	
	N	Hurd, C.D. and Hoffman, W.A. "Directed Ring Closure in the Synthesis of Chromans and Coumarans from ortho-Allylphenols". J. Am. Chem. Soc. 1940. 5:212-222.	
	0	Klint, T. and Weikop, P. "Monoamine transporters as continuing targets for drug discovery in depression". Drug Discovery Today: Therapeutic Strategies. 2004. 1(1):111-116.	
	Р	Kunz, K., et al. "Renaissance of Ullmann and Goldberg Reactions - Progress in Copper Catalyzed C-N-, C-O- and C-S-Coupling". Synlett. 2003. 15:2428-2439.	
	Q	March, J. Advanced Organic Chemistry: Reaction Mechanisms, and Structure. 3rd ed. 1985. New York, John Wiley & Sons. Pages 342-343; 589-590; 684-685.	
	R	Millan, M.J. "The neurobiology and control of anxious states". Progress in Neurobiology. 2003. 70:83-244.	
	S	Parham, W.E. and Jones, L.D. "Elaboration of BromoaryInitriles". J. Org. Chem. 1976. 41(7):1187-1191.	
$\sqrt{}$	т	Sakamuri, S., et al. "Pharmacophore-Based Discovery, Synthesis, and Biological Evaluation of 4-Phenyl-1-arylalkyl Piperidines as Dopamine Transporter Inhibitors". Bioorg. Med. Chem. Lett. 2001. 11:495-500.	

Examiner Signature	T.A. Solola	Date Considered	1-25-08
451/4441155			

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 10/31/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitu	Substitute for form 1449/PTO			Complete if Known		
				Application Number	10/551,869	
			CLOSURE	Filing Date	October 31, 2006	
STA	TEMENT B	Y A	PPLICANT	First Named Inventor	Ask Püschl	
	(Use as many she	ote se r	nocessary)	Art Unit	1625	
	(Use as many sheets as necessary)			Examiner Name	Not Yet Assigned	
Sheet	3	of	3	Attorney Docket Number	433-US-PCT	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
7°0	u	Sato, T., et al. "Selective inhibition of monoamine neurotransmitter transporters by synthetic local anesthetics". Naunyn-Schmiedeberg's Arch Pharmacol. 2000. 361:214-220.	
	v	Siemsen, P., et al. "Acetylenic Coupling: A Powerful Tool in Molecular Construction". Angew. Chem. Int. Ed. 2000. 39:2632-2657.	
	w	Silverman, R.B. The Organic Chemistry of Drug Design and Drug Action. 1992. San Diego. Academic Press. P.19.	
	х	Tamiz, A.P., et al. "Further SAR Studies of Piperidine-Based Analogues of Cocaine. 2. Potent Dopamine and Serotonin Reuptake Inhibitors". J. Med. Chem. 2000. 43(6):1215-1222.	
	Υ	Wang, S., et al. "Discovery of a Novel Dopamine Transporter Inhibitor, 4-Hydroxy-1-methyl-4-(4-methylphenyl)-3-piperidyl 4-Methylphenyl Ketone, as a Potential Cocaine Antagonist through 3D-Database Pharmacophore Searching. Molecular Modeling, Structure - Activity Relationships, and Behavioral Pharmacological Studies". J. Med. Chem. 2000. 43(3): 351-360.	
	·		
		•	

Examiner Signature	T. A. Solola	Date Considered	1-25-08

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (07-06)

Approved for use through 09/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

nder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449/PTO

(Use as many sheets as necessary)

Complete if Known					
Application Number	10/551,869				
Filing Date	September 30, 2005				
First Named Inventor	Ask Püschi				
Art Unit	1625				
Examiner Name	Not Yet Known				
Attorney Docket Number	433-US-PCT				

Examiner	Cite	Decument Number	Publication Date	F DOCUMENTS  Name of Patentee or	Pages, Columns, Lines, Where
Initials*	No.1	Document Number  Number-Kind Code <sup>2 (F known)</sup>	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Releva
10		<sup>US-</sup> 3,803,143	04-09-1974	Tanaka, S., et al.	,
$\neg$		<sup>US-</sup> 4,018,830	04-19-1977	Christy, M., et al.	
		<sup>US-</sup> 4,055,665	10-25-1977	Christy, M., et al.	
		<sup>US-</sup> 4,056,632	11-01-1977	Mehta, N., et al.	
		<sup>US-</sup> 4,198,417	04-15-1980	Ong, H., et al.	
		<sup>US-</sup> 4,241,071	12-23-1980	Martin, L., et al.	
		us- 5,095,039	03-10-1992	Mehta, N., et al.	
		US- 6,410,736 B1	06-25-2002	Howard, H., et al.	
		<sup>US-</sup> 6,436,938 B1	08-20-2002	Howard, H., et al.	
1/		<sup>US-</sup> 6,596,741 B2	07-22-2003	Howard, H., et al.	
-		US-			
		US-			

-		FORE	IGN PATENT DOCU	MENTS		
	Cite No.1		Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
			MM-DD-YYYY		Or Relevant Figures Appear	T°
70		WO 93/12080	06-24-1993	The Wellcome Foundation Limited		
7		WO 97/17325	05-15-1997	Farmak A.S.		
		WO 97/17352 A1	05-15-1997	Gist-Brocades B.V.		L
		WO 98/08817	03-05-1998	American Home Products Corp.		
		WO 00/66537	11-09-2000	Kung, Hank, F.		L
		WO 00/59878	10-12-2000	Icos Corp.		

Signature $1 - A = 20 000$ Considered $1 - 23 - 88$	Examiner Signature	1 142	50/ola	Date Considered	1-25-08
---	-----------------------	-------	--------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. The reference considered, whether or not citation is applicant, applicant unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. The reference considered, whether or not citation is allowed a serial number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation in attention in the communication in the communication in the citation is not considered. Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** 10/551,869 Filing Date September 30, 2005 INFORMATION DISCLOSURE First Named Inventor Ask Püschl STATEMENT BY APPLICANT Art Unit 1625 (Use as many sheets as necessary) **Examiner Name** Not Yet Known Sheet 2 433-US-PCT Attorney Docket Number

Examiner	024		U. S. PATENT D		D		
Initials* No.	No.1	No.1	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2 (F known)</sup>	<del></del>		Figures Appear		
		US-					
		U\$-					
		US-					
		US-					
		US-					
		US-					
		US-	1				
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
<del></del>		US-	<del>                                     </del>				
	<del></del>	US-	+				

		FORE	IGN PATENT DOCL	IMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>3</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T°
10		WO 01/10842 A2	02-15-2001	Millennium Pharm., Inc.		
		WO 01/27068 A1	04-19-2001	Pfizer Products Inc.		
		WO 02/062766 A2	08-15-2002	Millennium Pharm., Inc.		
		WO 02/098857 A1	12-12-2002	F. Hoffman-La Roche AG		
.17		WO 03/055873 A1	07-10-2003	H. Lundbeck A/S		
$\neg \forall$		EP 0 273 199 A2	07-06-1988	Laboratoires Hoechst SA		

Examiner Signature	7. A.	50 pla	Date Considered	1-25-08
	1 01	20100	 	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** 10/551,869 Filing Date September 30, 2005 INFORMATION DISCLOSURE First Named Inventor Ask Püschi STATEMENT BY APPLICANT Art Unit 1625 (Use as many sheets as necessary) **Examiner Name** Not Yet Known Attorney Docket Number 433-US-PCT Sheet 3

**U. S. PATENT DOCUMENTS** Examine **Publication Date** Name of Patentee or Pages, Columns, Lines, Where **Document Number** Initials\* MM-DD-YYYY **Applicant of Cited Document** Relevant Passages or Relevant Number-Kind Code<sup>2 (# known)</sup> Figures Appear US-US-US-US-US-US-US-ับร-US-US-US-ŪS-US-US-US-US-US-US-US-

Examiner	Cite	Foreign Patent Document	IGN PATENT DOCU	Name of Patentee or	Pages, Columns, Lines,	Г
Initials* No.1		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages Or Relevant Figures Appear	1
YD	<u> </u>	EP 0 396 827 A1	11-14-1990	SPOFA Spojene Podniky Pro		
		EP 0 402 097 A1	12-12-1990	The Wellcome Foundation Limited		
		EP 0 755 923 A1	01-29-1997	Suntory Limited		L
		EP 0 814 084 A1	12-29-1997	Eli Lilly and Co.		Γ
V		EP 0 921 124 A1	09-06-1999	Pfizer Limited		

Examiner Signature	T	7 Sple	la	Date Considered	1-25-08

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WiPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Nind of document by the appropriate symbols as indicated on the document under WiPO Standard ST.18 if possible. Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-08)

Approved for use through 09/30/2008. OMB 0851-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete If Known ubstitute for form 1449/PTO **Application Number** 10/551,869 INFORMATION DISCLOSURE Filing Date September 30, 2005 STATEMENT BY APPLICANT First Named Inventor Ask Püschl Art Unit 1625 (Use as many sheets as necessary) **Examiner Name** Not Yet Known **Attorney Docket Number** Sheet 433-US-PCT 1

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	T <sup>2</sup>
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	1*
Y0		Axford, L., et al. "Bicyclo[2.2.1]heptanes as Novel Triple Re-uptake inhibitors for the Treatment of Depression", Bioorganic & Medicinal Chemistry Letters, 2003, pages 3277-3280, vol. 13.	
		Edmond, P., et al. "Substituted Diphenyl Sulfides as Selective Serotonin Transporter Ligands: Synthesis and In Vitro Evaluation", J. Med. Chem., 2002, pages 1253-1258, vol. 45.	
		Hawkins, D.G., et al. "Competitive Cyclisation of Singlet and Triplet Nitrenes. Part 7. Reaction Pathways of 2-Azidophenyl Benzothienyl Azides", Journal of the Chemical Society, Perkin Transactions I: Organic and Bio-Organic Chemistry, 1979, pages 3207-3210, No. 12.	
		Jackson, A., et al. "Electrophilic Substitution in Indoles Part 16 1,2 The Formation of Indolobenzothiazines and Indolobenzothiazepines by Intramolecular Cyclisation of (o-Nitrophenylthio)indoles", J. Chem. Res. Miniprint, 1988, pages 2017-2063, vol. 9.	
		Jilek, J., et al. "Potential Antidepressants: 2-(Methoxy- and Hydroxy-Phenylthio)Benzylamines as Selective Inhibitors of 5-Hydroxytryptamine Re-Uptake in the Brain", Collect. Czech. Chem. Commun., 1989, pages 3294-3338, vol. 54.	
		Martin, L., et al. "Synthesis of Spiro[isobenzofuran-1(3H),4'-piperidines] as Potential Central Nervous System Agents. 5. Conformationally Mobile Analogues Derived by Furan Ring Opening", J. Med. Chem., 1979, pages 1347-1354, vol. 22, No. 11.	
		Oya, S., et al. "A New Single-Photon Emission Computed Tomography Imaging Agent for Serotonin Transporters: [123I] IDAM, 5-lodo-2-((2-((dimethylamino)methyl)-phenyl)thio)benzyl Alcohol", J. Med. Chem., 1999, pages 333-335, vol. 42 (3).	
		Oya, S., et al. "New PET Imaging Agent for the Serotonin Transporter: [18F]ACF (2-[(2-Amino-4-chloro-5-fluorophenyl)thio]-N,N-dimethyl-benzenmethanamine)", J. Med. Chem., 2002, pages 4716-4723, vol. 45.	
		Ragno, R., et al. "Docking and 3-D QSAR Studies on Indolyl Aryl Sulfones. Binding Mode Exploration at the HIV-1 Reverse Transcriptase Non-Nucleoside Binding Site and Design of Highly Active N-(2-Hydroxyethyl)carboxamide and N-(2-Hydroxyethyl)carbohydrazide Derivatives", J. Med. Chem., 2005, pages 213-223, vol. 48.	
V		Silvestri, R., et al. "Novel Indolyl Aryl Sulfones Active against HIV-1 Carrying NNRTI Resistance Mutations: Synthesis and SAR Studies", J. Med. Chemistry, 2003, pages 2482-2493, vol. 46.	

Examiner	T 1	$C \mid 1$	Date	1 25-00
Signature	l l'A	20101	(Considered	1270 00

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered, include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 09/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	te for form 1449/PTO	JUCION AC	tor 1995, no persons at	e required to respond to a conection	of information unless it contains a valid OMB control num Complete if Known	1007.
QUUSUU	W101101111 144011 14			Application Number	10/551,869	
INF	ORMATION	l DIS	CLOSURE	Filing Date	September 30, 2005	
STA	STATEMENT BY APPLICANT			First Named Inventor	Ask Püschl	
	(Use as many sh	00 <b>0</b> 0 00 00	anaeand	Art Unit .	1625	
	(Cat as many an	<del>ज्</del> याः ४३ ॥१	rcossa: y/	Examiner Name	Not Yet Known	
Sheet	2	of	2	Attorney Docket Number	433-US-PCT	

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>			
70		Sindelar, K., et al. "Potential Antidepressants and Inhibitors of 5-Hydroxy-Tryptamine and Noradrenaline Re-Uptake in the Brain: N,N-Dimethyl-(Arylthio)Thenylamines and N,N-Dimethyl-2-(Thienylthio) Benzylamines", Collect. Czech. Chem. Commun., 1991, pages 449-458, vol. 56.				
			ļ			

Examiner	-T 1	e 1 1	Date	10:5-00
Signature	1 · A	· Dololg	Considered	1-23 08

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Tredemark Office; U.S. DEPARTMENT OF COMMERCE

	Substitute for form 1449A/PTO				Complete if Known		
					Application Number	10/551,869	
	IN	<b>FORMATIO</b>	N DISCLO	SURE	Filing Date	September 30, 2005	
	STATEMENT BY APPLICANT			CÁNT	First Named Inventor	Ask Puschi	
·					Art Unit	Not Yet Known	
		(Use as many sl	neets as necessary)		Examiner Name	Not Yet Known	
S	heet	1	of	1	Attorney Docket Number	433-US-PCT	

			U. S. PATENT C	OCUMENTS	
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
	,	Number-Kind Code <sup>2 (# known)</sup>			Figures Appear
		us-	-		
		US-			
		US-			
		US-			· · · · · · · · · · · · · · · · · · ·
		US-			
		US-			
		US-			
	ļ	US-			
		US-			
		US-	· · · · · · · · · · · · · · · · · · ·		
		US-		· · · · · · · · · · · · · · · · · · ·	
		US-			
		US-			

	FOREIGN PATENT DOCUMENTS								
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	_ ,			
muais	190.	Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	MM-DD-TTTT	Applicant of Cited Document	or Relevant Figures Appear	<u> </u>			
<b>/</b> D		WO 03/029232 A1	04/10/2003	H. Lundbeck A/S					
1/		WO 01/49678 A1	07/12/2001	H. Lundbeck A/S	•				
				P	***************************************				

Examiner Signature	-t-A.	50/0/9	Date Considered	1-25-08

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.